Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer

Abstract Background ONC201 is a dopamine receptor D2 (DRD2) antagonist that inhibits tumor growth in preclinical models through ClpP activation to induce integrated stress response pathway and mitochondrial events related to inhibition of cell growth, which is being explored in clinical trials for s...

Full description

Bibliographic Details
Main Authors: Stuart R. Pierce, Ziwei Fang, Yajie Yin, Lindsay West, Majdouline Asher, Tianran Hao, Xin Zhang, Katherine Tucker, Allison Staley, Yali Fan, Wenchuan Sun, Dominic T. Moore, Chang Xu, Yi-Hsuan Tsai, Joel Parker, Varun Vijay Prabhu, Joshua E. Allen, Douglas Lee, Chunxiao Zhou, Victoria Bae-Jump
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
ONC201
DRD2
Endometrial cancer
Invasion
Proliferation
Online Access:https://doi.org/10.1186/s13046-021-01842-9

Internet

https://doi.org/10.1186/s13046-021-01842-9

Similar Items